Incretin-based therapies in type 2 diabetes: A review of clinical results

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.

Original languageEnglish
JournalDiabetes Research and Clinical Practice
Volume82
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Dec 15 2008

Fingerprint

Incretins
Type 2 Diabetes Mellitus
Glucose
Glucagon-Like Peptide 1
Therapeutics
Hypoglycemic Agents
Fasting
Clinical Trials
Safety
Weights and Measures
exenatide

Keywords

  • Diabetes mellitus
  • DPP-4 inhibitors
  • Exenatide
  • GLP-1 analogues
  • Sitagliptin
  • Vidagliptin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology

Cite this

@article{b8c544cf6b8f44a5827623c24766f017,
title = "Incretin-based therapies in type 2 diabetes: A review of clinical results",
abstract = "GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.",
keywords = "Diabetes mellitus, DPP-4 inhibitors, Exenatide, GLP-1 analogues, Sitagliptin, Vidagliptin",
author = "Emanuele Bosi and Pietro Lucotti and Emanuela Setola and Lucilla Monti and Piatti, {Pier Marco}",
year = "2008",
month = "12",
day = "15",
doi = "10.1016/j.diabres.2008.10.003",
language = "English",
volume = "82",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Incretin-based therapies in type 2 diabetes

T2 - A review of clinical results

AU - Bosi, Emanuele

AU - Lucotti, Pietro

AU - Setola, Emanuela

AU - Monti, Lucilla

AU - Piatti, Pier Marco

PY - 2008/12/15

Y1 - 2008/12/15

N2 - GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.

AB - GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.

KW - Diabetes mellitus

KW - DPP-4 inhibitors

KW - Exenatide

KW - GLP-1 analogues

KW - Sitagliptin

KW - Vidagliptin

UR - http://www.scopus.com/inward/record.url?scp=56949086428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56949086428&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2008.10.003

DO - 10.1016/j.diabres.2008.10.003

M3 - Article

C2 - 19022515

AN - SCOPUS:56949086428

VL - 82

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - SUPPL. 2

ER -